Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation
Objective: To assess the efficacy of Intra-operative Intravitreal Bevacizumab in treating Diabetic Macular Edema in patients undergoing Phacoemulsification with Foldable intraocular lens (IOL) Implantation, in comparison to a control group. Methodology: This experimental study was performed in depa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aziz Fatimah Medical and Dental College
2024-06-01
|
| Series: | Journal of Aziz Fatimah Medical and Dental College |
| Subjects: | |
| Online Access: | https://journal.afmdc.edu.pk/index.php/AFMDC/article/view/301 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586125662748672 |
|---|---|
| author | Haider Ali Chaudhry Gulnaz Irfan Ahmed Sualeh Muhammad Ahmad |
| author_facet | Haider Ali Chaudhry Gulnaz Irfan Ahmed Sualeh Muhammad Ahmad |
| author_sort | Haider Ali Chaudhry |
| collection | DOAJ |
| description |
Objective: To assess the efficacy of Intra-operative Intravitreal Bevacizumab in treating Diabetic Macular Edema in patients undergoing Phacoemulsification with Foldable intraocular lens (IOL) Implantation, in comparison to a control group.
Methodology: This experimental study was performed in department of Ophthalmology, Madinah Teaching Hospital, Faisalabad from 5th October to 2022 – 5th March 2023. Sixty patients (30 in each group) were enrolled in the study. Patients in group “A” received Intravitreal Bevacizumab immediately after phacoemulsification with foldable IOL implantation.Whereas Intravitreal Bevacizumab was not given to patients in group B (control group). Best Corrected Visual Acuity (BCVA) and macular thickness using optical coherence tomography (OCT) were recorded within a timeframe of 7-30 days prior to surgery, as well as at 1 and 3 months after the surgery for comparison between the two study groups.
Results: The study comprised 60 patients, with a mean age of 56.43 ± 5.90 years, representing both genders. Among the participants, males were predominant, accounting for 32 (53.3%) individuals, while females constituted 28 (46.7%) of the sample. The baseline best-corrected visual acuity (BCVA) measurements between group A and group B were 0.22 ± 0.68 and 0.21 ± 0.07, respectively. There was no statistically significant difference observed between the two groups (P = 0.677). However, significant disparities in BCVA were observed after one- and three-months post-surgery, favoring group A.Similarly, mean optical coherence tomography (OCT) at baseline was 271.09 ± 26.87 in group A and 307.57 ± 32.81 in group B, with no significant difference (P = 0.771). Nonetheless, significant differences in OCT were noted after one- and three-months post-surgery, with group A demonstrating superior results. These findings underscore the beneficial impact of intra-operative Bevacizumab in improving both BCVA and OCT outcomes post-surgery.
Conclusion: The administration of intravitreal bevacizumab during phacoemulsification has been shown to yield notable improvements in Best Corrected Visual Acuity (BVCA) and Optical Coherence Tomography (OCT) among those with diabetes with macular edema who are undergoing cataract surgery.
|
| format | Article |
| id | doaj-art-5090ada5a3b944edb27996a697a7a438 |
| institution | Kabale University |
| issn | 2706-7238 2706-7246 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Aziz Fatimah Medical and Dental College |
| record_format | Article |
| series | Journal of Aziz Fatimah Medical and Dental College |
| spelling | doaj-art-5090ada5a3b944edb27996a697a7a4382025-01-26T08:46:01ZengAziz Fatimah Medical and Dental CollegeJournal of Aziz Fatimah Medical and Dental College2706-72382706-72462024-06-016110.55279/jafmdc.v6i1.301Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL ImplantationHaider Ali ChaudhryGulnazIrfan Ahmed SualehMuhammad Ahmad Objective: To assess the efficacy of Intra-operative Intravitreal Bevacizumab in treating Diabetic Macular Edema in patients undergoing Phacoemulsification with Foldable intraocular lens (IOL) Implantation, in comparison to a control group. Methodology: This experimental study was performed in department of Ophthalmology, Madinah Teaching Hospital, Faisalabad from 5th October to 2022 – 5th March 2023. Sixty patients (30 in each group) were enrolled in the study. Patients in group “A” received Intravitreal Bevacizumab immediately after phacoemulsification with foldable IOL implantation.Whereas Intravitreal Bevacizumab was not given to patients in group B (control group). Best Corrected Visual Acuity (BCVA) and macular thickness using optical coherence tomography (OCT) were recorded within a timeframe of 7-30 days prior to surgery, as well as at 1 and 3 months after the surgery for comparison between the two study groups. Results: The study comprised 60 patients, with a mean age of 56.43 ± 5.90 years, representing both genders. Among the participants, males were predominant, accounting for 32 (53.3%) individuals, while females constituted 28 (46.7%) of the sample. The baseline best-corrected visual acuity (BCVA) measurements between group A and group B were 0.22 ± 0.68 and 0.21 ± 0.07, respectively. There was no statistically significant difference observed between the two groups (P = 0.677). However, significant disparities in BCVA were observed after one- and three-months post-surgery, favoring group A.Similarly, mean optical coherence tomography (OCT) at baseline was 271.09 ± 26.87 in group A and 307.57 ± 32.81 in group B, with no significant difference (P = 0.771). Nonetheless, significant differences in OCT were noted after one- and three-months post-surgery, with group A demonstrating superior results. These findings underscore the beneficial impact of intra-operative Bevacizumab in improving both BCVA and OCT outcomes post-surgery. Conclusion: The administration of intravitreal bevacizumab during phacoemulsification has been shown to yield notable improvements in Best Corrected Visual Acuity (BVCA) and Optical Coherence Tomography (OCT) among those with diabetes with macular edema who are undergoing cataract surgery. https://journal.afmdc.edu.pk/index.php/AFMDC/article/view/301Diabetic Macular EdemaCataractIntraoperative Intravitreal BevacizumabPhacoemulsification |
| spellingShingle | Haider Ali Chaudhry Gulnaz Irfan Ahmed Sualeh Muhammad Ahmad Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation Journal of Aziz Fatimah Medical and Dental College Diabetic Macular Edema Cataract Intraoperative Intravitreal Bevacizumab Phacoemulsification |
| title | Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation |
| title_full | Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation |
| title_fullStr | Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation |
| title_full_unstemmed | Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation |
| title_short | Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation |
| title_sort | intra operative intravitreal bevacizumab for patients with diabetic macular edema undergoing phacoemulsification with foldable iol implantation |
| topic | Diabetic Macular Edema Cataract Intraoperative Intravitreal Bevacizumab Phacoemulsification |
| url | https://journal.afmdc.edu.pk/index.php/AFMDC/article/view/301 |
| work_keys_str_mv | AT haideralichaudhry intraoperativeintravitrealbevacizumabforpatientswithdiabeticmacularedemaundergoingphacoemulsificationwithfoldableiolimplantation AT gulnaz intraoperativeintravitrealbevacizumabforpatientswithdiabeticmacularedemaundergoingphacoemulsificationwithfoldableiolimplantation AT irfanahmedsualeh intraoperativeintravitrealbevacizumabforpatientswithdiabeticmacularedemaundergoingphacoemulsificationwithfoldableiolimplantation AT muhammadahmad intraoperativeintravitrealbevacizumabforpatientswithdiabeticmacularedemaundergoingphacoemulsificationwithfoldableiolimplantation |